ITGAM and psoriasis: It has been shown that CD11b and CD66b were higher in severe psoriasis patients than moderately psoriatic patients and normal healthy controls, while neutrophils from psoriasis patients receiving biologic treatment (infliximab or ustekinumab) had normal CD11b and CD66b levels.